PIK3CA and ovarian carcinoma: In addition, a combination regimen of PARPi and copanlisib (a PI3K inhibitor) was tested in phase I/II trials (NCT03586661 and NCT05295589) in patients with BRCA-mutated, resistant ovarian cancer.